Live
NHS Framework - Blood Disorders including Haemophilia A and B - July 2024
£765,000,000
NHS EnglandPfizer Ltd
goods
Contract Details
- Tender Value
- £765,000,000
- Stage
- Live
- Published
- Awarded
Timeline
Awarded
Start
Disclosed
End
Description
Project Title: NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A and B - July 2024 Offer reference number: CM/PHS/22/5661 Period of framework: 1 July 2024 to 30 April 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
Related Contracts
From This Buyer
- NHS England Bowel Cancer Screening Programme Managed Service
£210,462,766 ·
- Mural (Whiteboard) Enterprise Licenses 2026
£59,030 ·
- Cabinet Office Media Monitoring Unit
£14,000 ·
- PAS Silverlink Reprocurement 2026
£59,030 ·
From This Supplier
- Pneumococcal vaccine for adults and at risk groups (2025)
£1 ·
- NHS National Generic Pharmaceuticals Wave 13
£469,741,550 ·
- Bleeding Disorders including Haemophilia B
£250,000,000 ·
- NHS National Generic Pharmaceuticals Wave 13
£469,741,550 ·
In This Category
Ref: 1bf0e552-e90a-4ae2-996e-5478f81f7fca-770315 · Sourced from Contracts Finder
View source notice